20451 Seneca Meadows Parkway
About SenseonicsWe are a medical technology company focused on the design, development and commercialization of glucose monitoring systems to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our first generation continuous glucose monitoring, or CGM, system is a reliable, long-term, implantable CGM system that we have designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 days, as compared to five to seven days for currently available CGM systems.
CEO: Timothy T. Goodnow, PhD
CFO: R. Don Elsey
Chief Medical Officer: E. Lynne Kelley, M.D., FACS
63 articles with Senseonics
Senseonics Holdings, Inc. announced the pricing of a registered underwritten public offering of 22,727,273 shares of its common stock at a price to the public of $1.10 per share.
Senseonics Holdings, Inc. announced the pricing of an $82.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Senseonics Holdings, Inc. announced preliminary financial results for the second quarter of 2019.
Senseonics Holdings, Inc. announced that it has commenced a registered underwritten public offering of $25.0 million of its shares of common stock.
Senseonics Holdings, Inc. announced the commencement of an offering of $80.0 million aggregate principal amount of 5.25% convertible senior notes due 2025 and the commencement of a consent solicitation in respect of its outstanding 5.25% convertible senior subordinated notes due 2023.
Study presented at ADA's Scientific Sessions compared insulin-only mode of iLet to usual care
Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System
Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that they received FDA approval for the non-adjunctive indication (dosing claim) for the Eversense Continuous Glucose Monitoring System.
Senseonics Holdings, Inc. announced the company plans to participate in the upcoming Raymond James Life Sciences and MedTech Conference in New York, NY.
Senseonics Holdings, Inc. reported financial results for the quarter ended March 31, 2019.
Patients Can Access Long-term Eversense CGM for only $99* Under Program
Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, reported financial results for the fourth quarter and full year ended December 31, 2018.
Senseonics is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes
Senseonics Holdings, Inc. announced the integration of Eversense CGM data into the Glooko diabetes data management platform.
Reports Preliminary Fourth Quarter and Full Year 2018 Revenue Results and Issues 2019 Financial Guidance
Now patients who need to have an MRI* do not need to remove the Eversense Sensor
Senseonics Holdings, Inc. today announced the appointment of Jon D. Isaacson as the company’s Chief Financial Officer, effective immediately.
Senseonics Announces First Study Participant Implanted in the U.S. as Part of the PROMISE 180-Day Sensor Clinical Study and the Submission of Key PMA Supplements to the FDA to Advance Current 90-Day Product
Senseonics Holdings, Inc. today announced that the extended life Eversense® XL sensor that lasts up to 180 days has been implanted in the first U.S. study participant as part of the clinical trial for pre-market application submission to the Food and Drug Administration.
Senseonics Holdings, Inc. today announced the retirement of Chief Financial Officer, R. Don Elsey. Mr. Elsey has agreed to remain in his current role and to step down when a replacement is appointed.
Senseonics Announces FDA Approval to Expand Eversense® CGM Certification to Nurse Practitioners and Physician Assistants
--Now all qualified healthcare providers can perform sensor placements on patients--
Senseonics Holdings, Inc. today announced that Aetna, the third largest commercial health plan provider in the United States, is providing coverage for Eversense, effective immediately.